 |
인쇄하기
취소
|
CJ extends its business sphere to local anti-migraine market with GlaxoSmithKline's Naramig
CJ announced that it would introduce Naramig, anti-migraine drug in domestic pharmaceutical market through its exclusive distribution agreement with GlaxoSmithKline, which was duly executed on July 28.
CJ officials said that Naramig tablet 2.5 mg is a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction and is recommended as monotherapy for the acute tr...
CJ officials said that Naramig tablet 2.5 mg is a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction and is recommended as monotherapy for the acute tr...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.